Recurrent Solid Neoplasm Recruiting Phase 1 / 2 Trials for DB09035 (Nivolumab)

IndicationStatusPhase
DBCOND0080814 (Recurrent Solid Neoplasm)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02304458Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasTreatment